TABLE 2.

Primary and Secondary Outcomes With Canagliflozin 100 mg and 300 mg Combined (n = 11)

Baseline Mean (SD)First Follow-Up, Mean (SD)Difference: Baseline to First Follow-UpPSecond Follow-Up, Mean (SD)Difference: Baseline to Second Follow-UpP
A1C, %8.06 (1.11)7.40 (0.99)–0.660.001***7.35 (0.94)–0.710.001***
BMI, kg/m235.36 (5.26)34.37 (5.48)–0.980.013**33.40 (4.62)–1.950.056*
Weight, kg103.78 (17.75)101.05 (19.34)–2.730.022**98.65 (19.98)–5.130.054*
SBP, mmHg117.27 (13.78)116.00 (6.93)–1.270.758118.00 (14.91)0.730.789
DBP, mmHg72.36 (16.10)68.36 (8.80)–4.000.33067.64 (10.73)–4.730.331
  • * Significant at α = 0.10.

  • ** Significant at α = 0.05.

  • *** Significant at α = 0.01.